Skip to content
Narrow screen resolution Wide screen resolution Auto adjust screen size Increase font size Decrease font size Default font size

AMDA Foundation

Home arrow Research Network arrow Current Research Projects arrow Alzheimer’s Disease arrow Use of the Rivastigmine (Exelon®) Patch in Assisted Living and Long-Term Care Facilities
Use of the Rivastigmine (Exelon®) Patch in Assisted Living and Long-Term Care Facilities PDF Print E-mail
Category Alzheimer’s Disease
Title Use of the Rivastigmine (Exelon®) Patch in Assisted Living and Long-Term Care Facilities - Staff Preference Over Other Forms of Cholinesterase Inhibitor Therapy
Aim The AMDA Foundation Research Network will explore whether the rivastigmine patch is preferred over other forms of cholinesterase inhibitor therapy in skilled nursing and long-term care facilities.

The study team will determine whether:
  1. The rivastigmine patch provides a preferred method of delivery by those staff members dispensing the medication
  2. The rivastigmine patch users were deemed easier to care for in the last month by the caregiving staff (i.e., CNAs, Care Partners) compared to other residents on other cholinesterase inhibitors that are under their care
  3. The rivastigmine patch users have fewer episodes of charted gastrointestinal complaints or medications administered that are used for gastrointestinal complaints than residents on oral cholinesterase inhibitors
  4. The rivastigmine patch users are more compliant with the patch than with the medications they receive orally
Investigators Stefan Gravenstein, MD, CMD; Larry Lawhorne, MD

AMDA Foundation is currently seeking Investigators for this project. Click here for more information.
Citation
Recruitment The AMDA Foundation is looking to recruit several long term care facilities for participation in this study. Participating facilities must currently prescribe their residents the rivastigmine patch. The goal is to have nurses and medication dispensers complete 800 medication preference surveys for patients currently taking the rivastigmine patch and for patients taking traditional oral medication for AD.
 
[ Back ]